Francois Clement Bidard

home / authors / francois-clement-bidard

Articles

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Joyce O’Shaughnessy, MD;Francois Clement Bidard;Phillipe Aftimos;Javier Cortes;Janice Lu, MD, PhD ;Giulia Tonini;Kathy Puyana Theall;Alessandro Paoli;Virginia Kaklamani, MD, DSc
August 24th 2024
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

Philippe Aftimos;Javier Cortes;Francois Clement Bidard;Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;Patrick Neven, MD, PhD
April 28th 2023
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Aditya Bardia, MD, MPH;Francois Clement Bidard;Patrick Neven, MD, PhD;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Philippe Aftimos;Javier Cortes;Simona Scartoni;Nassir Habboubi;Virginia Kaklamani, MD, DSc
April 28th 2023

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
Published: April 21st 2021 | Updated: April 22nd 2025
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma